

## ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--([BUSINESS WIRE](#))--[ImmunoGen, Inc.](#) (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will participate in two investor conferences in the coming weeks. A live webcast of each can be accessed through the "Investor Information" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay will be available at the same location for one week.

- **RBC Capital Markets' Healthcare Conference**  
2:05 p.m. ET on March 2, 2011 in New York, NY  
"Fireside chat" with Daniel Junius, President and CEO
- **Cowen and Company 31<sup>st</sup> Annual Health Care Conference**  
9:30 a.m. ET on March 9, 2011 in Boston, MA  
Presentation by Gregory Perry, Senior Vice President and CFO

### About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen's collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

SOURCE: ImmunoGen, Inc.

### For Investors:

ImmunoGen, Inc.  
Carol Hausner, 781-895-0600  
Executive Director, Investor Relations and Corporate Communications  
[info@immunogen.com](mailto:info@immunogen.com)

or

### For Media:

The Yates Network  
Barbara Yates, 781-258-6153